ScholarIQanswers from OpenAlex & ORCID
Michel Meignan
ResearcherPublications, citations & collaboration network
Michel Meignan is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Michel Meignan have?
ScholarIQindexed works
Michel Meignan has 348 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Michel Meignan have?
ScholarIQcitation count
Michel Meignan has 18,590 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Michel Meignan?
ScholarIQh-index
Michel Meignan has an h-index of 63 in OpenAlex.
What is the i10-index of Michel Meignan?
ScholarIQi10-index
Michel Meignan has an i10-index of 163 in OpenAlex.
What is the ORCID of Michel Meignan?
ScholarIQorcid
The ORCID for Michel Meignan is on the source record.
What is the OpenAlex record for Michel Meignan?
ScholarIQopenalex
The OpenAlex for Michel Meignan is on the source record.
What are the most-cited papers on Michel Meignan?
ScholarIQmost cited works
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
Sally F. Barrington, N. George Mikhaeel, Lale Kostakoğlu, Michel Meignan, Martin Hutchings, Stefan Müeller, Lawrence H. Schwartz, Emanuele Zucca, Richard I. Fisher, Judith Trotman, Otto S. Hoekstra, Rodney J. Hicks, Michael O’Doherty, Roland Hustinx, Alberto Biggi, Bruce D. Cheson
Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
Judith Trotman, Stefano Luminari, Sami Boussetta, Annibale Versari, Jehan Dupuis, Christelle Tychyj, Luigi Marcheselli, Alina Berriolo-Riedinger, Antonella Franceschetto, Anne Julian, Fabien Ricard, Luca Guerra, Corinne Haïoun, Irène Biasoli, Hervé Tilly, Massimo Federico, Gilles Salles, Michel Meignan
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
Judith Trotman, Sally F. Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter Fingerle‐Rowson, Jiawen Zhu, Tina Nielsen, Deniz Şahin, Wolfgang Hiddemann, Robert Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine S. Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van Eygen, Randeep Sangha, Pam McKay, Jonathan Wilson, Richard van der Jagt, Daryl Roitman, Marek Trněný, Jiřı́ Mayer, Katell Le Dû, Philippe Solal‐Céligny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange‐Krex, Axel Florschütz, Hans‐Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Heß, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling‐Kaiser, Martin Hoffmann, Zita Borbényi, M. Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Párraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, José Antonio Márquez Navarro, Carlos Grande García, Herman Nilsson‐Ehle, Helen O. McCarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin J.S. Dyer, Ruth Pettengell, John Seymour, John G. Gribben, Saad Al‐Ismail, F. N. Al‐Refaie, Norbert Blesing, Christopher Macnamara, Ann O’Callaghan, Andrew Haynes, George Follows, Roderick J. Johnson, David Cunningham, Kristian M. Bowles, Graham P. Collins, Eve Gallop‐Evans, Stephen Robinson, Chezhian Subash